Sanral Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 24-10-2024
- Paid Up Capital ₹ 1.00 M
as on 24-10-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.80 Cr
as on 24-10-2024
- Satisfied Charges ₹ 0.38 M
as on 24-10-2024
- Revenue -8.03%
(FY 2023)
- Profit 7.15%
(FY 2023)
- Ebitda 17.42%
(FY 2023)
- Net Worth 15.42%
(FY 2023)
- Total Assets 7.73%
(FY 2023)
About Sanral Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.80 Cr. The company has closed loans amounting to ₹0.38 M, as per Ministry of Corporate Affairs (MCA) records.
Bhaga Ram and Narayan Chaudhary serve as directors at the Company.
- CIN/LLPIN
U24232RJ2015PTC047976
- Company No.
047976
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jodhpur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sanral Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhaga Ram  | Director | 29-Jul-2015 | Current |
| Narayan Chaudhary | Director | 29-Jul-2015 | Current |
Financial Performance of Sanral Pharma.
Sanral Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.03% decrease. The company also saw a slight improvement in profitability, with a 7.15% increase in profit. The company's net worth Soared by an impressive increase of 15.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sanral Pharma?
In 2023, Sanral Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rolence Pharma And Chemicals Limited Lia Bility PartnershipActive 8 years 10 monthsNarayan Chaudhary is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 06 Sep 2023 | ₹1.52 M | Open |
Others Creation Date: 18 Oct 2022 | ₹5.00 M | Open |
Others Creation Date: 20 Dec 2021 | ₹1.48 M | Open |
How Many Employees Work at Sanral Pharma?
Unlock and access historical data on people associated with Sanral Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sanral Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sanral Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
